Similar articles

• Reply to prostate-specific antigen screening for prostate cancer and the risk of overt metastatic disease at presentation : analysis of trends over time.

  Scosyrev E, Messing EM. Scosyrev E, et al. Cancer. 2013 Mar 1;119(5):1113-4. doi: 10.1002/cncr.27875. Epub 2012 Oct 23. Cancer. 2013. PMID: 23097014 No abstract available.
• Author's Reply to Srinivas: "Modeling the Relationship Between Exposure to Abiraterone and Prostate-Specific Antigen Dynamics in Patients with Metastatic Castration-Resistant Prostate Cancer".

  Xu S, De Porre P. Xu S, et al. Clin Pharmacokinet. 2017 Feb;56(2):213-214. doi: 10.1007/s40262-016-0469-1. Clin Pharmacokinet. 2017. PMID: 27815867 No abstract available.
• Reply to N. Fossati et al.

  Pisansky TM, Stish BJ. Pisansky TM, et al. J Clin Oncol. 2017 Feb;35(4):470-471. doi: 10.1200/JCO.2016.70.6119. Epub 2016 Nov 7. J Clin Oncol. 2017. PMID: 28129528 No abstract available.
• Problems in the determination of prostate specific antigen.

  Stenman UH, Leinonen J, Zhang WM. Stenman UH, et al. Eur J Clin Chem Clin Biochem. 1996 Sep;34(9):735-40. Eur J Clin Chem Clin Biochem. 1996. PMID: 8891526 Review.
• Prostate-specific antigen and prostate cancer: prediction, detection and monitoring.

  Lilja H, Ulmert D, Vickers AJ. Lilja H, et al. Nat Rev Cancer. 2008 Apr;8(4):268-78. doi: 10.1038/nrc2351. Nat Rev Cancer. 2008. PMID: 18337732 Review.